COVID-19 and hormonal contraception
Authors:
Open Access
- 25 January 2022
- journal article
- editorial
- Published by Elsevier in Case Reports in Women's Health
- Vol. 34, e00389
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom StudyPLOS ONE, 2021
- Estrogen receptors are linked to angiotensin-converting enzyme 2 (ACE2), ADAM metallopeptidase domain 17 (ADAM-17), and transmembrane protease serine 2 (TMPRSS2) expression in the human atrium: insights into COVID-19Hypertension Research, 2021
- ACE2 in the second act of COVID‐19 syndrome: Peptide dysregulation and possible correction with oestrogenJournal of Neuroendocrinology, 2021
- Change in Covid-19 infection and mortality rates in postmenopausal womenMenopause, 2021
- Age-related difference in the rate of coronavirus disease 2019 mortality in women versus menAmerican Journal of Obstetrics and Gynecology, 2020
- Estradiol, Progesterone, Immunomodulation, and COVID-19 OutcomesEndocrinology, 2020
- Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y HemostasiaMaturitas, 2020
- Contraception during Coronavirus-Covid 19 pandemia. Recommendations of the Board of the Italian Society of ContraceptionThe European Journal of Contraception & Reproductive Health Care, 2020
- Hormonal contraception: venous and arterial diseaseThe European Journal of Contraception & Reproductive Health Care, 2017
- Chronic estradiol treatment reduces platelet responses and protects mice from thromboembolism through the hematopoietic estrogen receptor αBlood, 2012